1994
DOI: 10.1007/978-3-642-78490-3_17
|View full text |Cite
|
Sign up to set email alerts
|

Beyond Pasteur to 2001: Future Trends in Lyssavirus Research?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

1996
1996
2014
2014

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 66 publications
0
2
0
Order By: Relevance
“…Administration of such MAbs protected animals when challenged with a lethal dose of rabies virus in experimental PEP models [ 139 ]. These data strongly suggest that MAbs, alone or in combination with vaccine, may be an effective method of protection against clinically relevant lyssaviruses [ 140 ]. Such an approach has several theoretical advantages over presently used hyperimmune sera: fi rst, in contrast to current products, comparatively small volumes of MAbs would have to be inoculated for equivalent active protein content, because specifi c neutralizing activity per mass of protein is higher, so MAbs may be optimal for lessening the trauma and pain of local wound infi ltration with a source of passive antibodies, and second, safety issues arising from the possibility of adventitious agents associated with human or animal blood products would be alleviated by bulk production under modern GMP conditions in cell culture.…”
Section: )mentioning
confidence: 91%
“…Administration of such MAbs protected animals when challenged with a lethal dose of rabies virus in experimental PEP models [ 139 ]. These data strongly suggest that MAbs, alone or in combination with vaccine, may be an effective method of protection against clinically relevant lyssaviruses [ 140 ]. Such an approach has several theoretical advantages over presently used hyperimmune sera: fi rst, in contrast to current products, comparatively small volumes of MAbs would have to be inoculated for equivalent active protein content, because specifi c neutralizing activity per mass of protein is higher, so MAbs may be optimal for lessening the trauma and pain of local wound infi ltration with a source of passive antibodies, and second, safety issues arising from the possibility of adventitious agents associated with human or animal blood products would be alleviated by bulk production under modern GMP conditions in cell culture.…”
Section: )mentioning
confidence: 91%
“…The technology of production of long acting (repository) animal vaccines is available, but we are not aware of any manufacturers who are doing developmental work for such products since such products are of little interest in Europe, America, Japan, Australia, Korea or other profitable markets [1,4]. Oral vaccination of stray (community) dogs with one of new recombinant rabies vaccines is possible and could probably be employed for mass vaccination if there is a will on the part of governments [6,7]. Such new technologies need to be urgently studied in field trials at suitable locations where there is a large population of stray dogs with endemic rabies.…”
Section: Methodsmentioning
confidence: 99%
“…Considering future vaccine candidates, given the revolution in genetics, various viruses could be used as expression vectors, for incorporation of foreign genes. Some agents could be constructed by the creation of transgenic vectors, expressing the immunogen of interest in an appropriate context (56). Extrapolating from the concepts of remote delivery and natural hypodermics, ectoparasites may be designed to harbour and administer vaccine vectors of interest.…”
Section: Vaccine Delivery To Wildlife: the Example Of Rabiesmentioning
confidence: 99%